These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 16944997)

  • 1. Budesonide for ulcerative colitis.
    Marín-Jiménez I; Peña AS
    Rev Esp Enferm Dig; 2006 May; 98(5):362-73. PubMed ID: 16944997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel extended release budesonide formulation for treatment of ulcerative colitis.
    Farkas K; Molnár T
    Expert Opin Pharmacother; 2014 Jan; 15(1):131-7. PubMed ID: 24219763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reviewing the therapeutic role of budesonide in Crohn's disease.
    López-Sanromán A; Clofent J; Garcia-Planella E; Menchén L; Nos P; Rodríguez-Lago I; Domènech E
    Gastroenterol Hepatol; 2018; 41(7):458-471. PubMed ID: 30007787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of oral budesonide in the treatment of active distal ulcerative colitis.
    Kolkman JJ; Möllmann HW; Möllmann AC; Penã AS; Greinwald R; Tauschel HD; Hochhaus G
    Drugs Today (Barc); 2004 Jul; 40(7):589-601. PubMed ID: 15510233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Budesonide with multi-matrix technology as second-line treatment for ulcerative colitis: evaluation of long-term cost-effectiveness in the Netherlands.
    Gherardi A; Roze S; Kuijvenhoven J; Ghatnekar O; Yip Sonderegger YL
    J Med Econ; 2018 Sep; 21(9):869-877. PubMed ID: 29857775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Budesonide MMX: efficacy and safety profile in the treatment of ulcerative colitis.
    Salice M; Rizzello F; Calabrese C; Privitera Hrustemovic H; Gionchetti P
    Expert Rev Gastroenterol Hepatol; 2019 Jul; 13(7):607-613. PubMed ID: 31106602
    [No Abstract]   [Full Text] [Related]  

  • 7. Oral budesonide for induction of remission in ulcerative colitis.
    Sherlock ME; Seow CH; Steinhart AH; Griffiths AM
    Cochrane Database Syst Rev; 2010 Oct; (10):CD007698. PubMed ID: 20927762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of Budesonide-MMX in active ulcerative colitis.
    Gionchetti P; Praticò C; Rizzello F; Calafiore A; Capozzi N; Campieri M; Calabrese C
    Expert Rev Gastroenterol Hepatol; 2014 Mar; 8(3):215-22. PubMed ID: 24502535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis.
    Löfberg R; Danielsson A; Suhr O; Nilsson A; Schiöler R; Nyberg A; Hultcrantz R; Kollberg B; Gillberg R; Willén R; Persson T; Salde L
    Gastroenterology; 1996 Jun; 110(6):1713-8. PubMed ID: 8964395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Budesonide multi-matrix system formulation for treating ulcerative colitis.
    Prantera C; Scribano ML
    Expert Opin Pharmacother; 2014 Apr; 15(6):741-3. PubMed ID: 24484392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral locally active steroids in inflammatory bowel disease.
    Nunes T; Barreiro-de Acosta M; Marin-Jiménez I; Nos P; Sans M
    J Crohns Colitis; 2013 Apr; 7(3):183-91. PubMed ID: 22784947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical trial: Preliminary efficacy and safety study of a new Budesonide-MMX® 9 mg extended-release tablets in patients with active left-sided ulcerative colitis.
    D'Haens GR; Kovács A; Vergauwe P; Nagy F; Molnár T; Bouhnik Y; Weiss W; Brunner H; Lavergne-Slove A; Binelli D; Di Stefano AF; Marteau P
    J Crohns Colitis; 2010 Jun; 4(2):153-60. PubMed ID: 21122499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis.
    Danese S; Siegel CA; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2014 May; 39(10):1095-103. PubMed ID: 24641622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. U.S. Budesonide enema study group.
    Hanauer SB; Robinson M; Pruitt R; Lazenby AJ; Persson T; Nilsson LG; Walton-Bowen K; Haskell LP; Levine JG
    Gastroenterology; 1998 Sep; 115(3):525-32. PubMed ID: 9721148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease.
    Edsbäcker S; Andersson T
    Clin Pharmacokinet; 2004; 43(12):803-21. PubMed ID: 15355126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Budesonide and inflammatory bowel disease].
    Gomollón F; Hinojosa J; Nos P
    Gastroenterol Hepatol; 1999 Dec; 22(10):525-32. PubMed ID: 10650668
    [No Abstract]   [Full Text] [Related]  

  • 17. Budesonide versus prednisolone retention enemas in active distal ulcerative colitis.
    Löfberg R; Ostergaard Thomsen O; Langholz E; Schiöler R; Danielsson A; Suhr O; Graffner H; Påhlman L; Matzen P; Møller-Petersen JF
    Aliment Pharmacol Ther; 1994 Dec; 8(6):623-9. PubMed ID: 7696452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral budesonide therapy for steroid-dependent ulcerative colitis: a pilot trial.
    Keller R; Stoll R; Foerster EC; Gutsche N; Domschke W
    Aliment Pharmacol Ther; 1997 Dec; 11(6):1047-52. PubMed ID: 9663828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Budesonide MMX for the Induction of Remission of Mild to Moderate Ulcerative Colitis: A Pooled Safety Analysis.
    Lichtenstein GR; Travis S; Danese S; D'Haens G; Moro L; Jones R; Huang M; Ballard ED; Bagin R; Hardiman Y; Collazo R; Sandborn WJ
    J Crohns Colitis; 2015 Sep; 9(9):738-46. PubMed ID: 26094251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Budesonide in inflammatory bowel disease: a meta-analysis].
    Nos P; Hinojosa J; Gomollón F; Ponce J
    Med Clin (Barc); 2001 Jan; 116(2):47-53. PubMed ID: 11181269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.